157 related articles for article (PubMed ID: 38026963)
1. CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients.
Majam T; Sukasem C; Reungwetwattana T; Chansriwong P; Atasilp C; Trachu N; Thamrongjirapat T; Sukprasong R; Meanwatthana J
Front Pharmacol; 2023; 14():1222435. PubMed ID: 38026963
[No Abstract] [Full Text] [Related]
2. Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer.
Veerman GDM; Boosman RJ; Jebbink M; Oomen-de Hoop E; van der Wekken AJ; Bahce I; Hendriks LEL; Croes S; Steendam CMJ; de Jonge E; Koolen SLW; Steeghs N; van Schaik RHN; Smit EF; Dingemans AC; Huitema ADR; Mathijssen RHJ
EClinicalMedicine; 2023 May; 59():101955. PubMed ID: 37125403
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
4. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
[TBL] [Abstract][Full Text] [Related]
6. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
Tang YJ; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291877
[TBL] [Abstract][Full Text] [Related]
7. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.
Cho BC; Chewaskulyong B; Lee KH; Dechaphunkul A; Sriuranpong V; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cheng Y; Cho EK; Voon PJ; Lee JS; Mann H; Saggese M; Reungwetwattana T; Ramalingam SS; Ohe Y
J Thorac Oncol; 2019 Jan; 14(1):99-106. PubMed ID: 30240852
[TBL] [Abstract][Full Text] [Related]
9. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
10. Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated
Yoshimura A; Yamada T; Okuma Y; Fukuda A; Watanabe S; Nishioka N; Takeda T; Chihara Y; Takemoto S; Harada T; Hiranuma O; Shirai Y; Nishiyama A; Yano S; Goto Y; Shiotsu S; Kunimasa K; Morimoto Y; Iwasaku M; Kaneko Y; Uchino J; Kenmotsu H; Takahashi T; Takayama K
Transl Lung Cancer Res; 2021 Aug; 10(8):3582-3593. PubMed ID: 34584858
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib for
Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
[TBL] [Abstract][Full Text] [Related]
12. Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
Morimoto K; Yamada T; Takeda T; Shiotsu S; Date K; Tamiya N; Goto Y; Kanda H; Chihara Y; Kunimatsu Y; Katayama Y; Iwasaku M; Tokuda S; Takayama K
Target Oncol; 2023 Sep; 18(5):657-665. PubMed ID: 37610516
[TBL] [Abstract][Full Text] [Related]
13. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
14. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of patients taking first-generation EGFR-TKIs may predict the benefits afforded by osimertinib in EGFR T790M-mutant NSCLC patients.
Meng H; Huang L; Wang J; Zhou Y; Wang M; Yang Z; Hong X
Int J Clin Pract; 2021 Dec; 75(12):e14877. PubMed ID: 34525256
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
[TBL] [Abstract][Full Text] [Related]
17. First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic.
Lakkunarajah S; Truong PT; Bone JN; Hughesman C; Yip S; Alex D; Hart J; Pollock P; Egli S; Clarkson M; Lesperance M; Ksienski D
Transl Lung Cancer Res; 2023 Jul; 12(7):1454-1465. PubMed ID: 37577326
[TBL] [Abstract][Full Text] [Related]
18. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA; Han JY; Dafni U; Cho BC; Yeo CM; Nadal E; Carcereny E; de Castro J; Sala MA; Bernabé R; Coate L; Provencio Pulla M; Garcia Campelo R; Cuffe S; Hashemi SMS; Früh M; Massuti B; Garcia-Sanchez J; Dómine M; Majem M; Sanchez-Torres JM; Britschgi C; Pless M; Dimopoulou G; Roschitzki-Voser H; Ruepp B; Rosell R; Stahel RA; Peters S;
Ann Oncol; 2022 Feb; 33(2):181-192. PubMed ID: 34839016
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer.
Yamazaki M; Komizo N; Iihara H; Hirose C; Yanase K; Yamada Y; Endo J; Yamashita S; Ohno Y; Todoroki K; Suzuki A; Hayashi H
Anticancer Res; 2023 Feb; 43(2):725-732. PubMed ID: 36697059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]